Evidence map›Paper›PMID 29142426›Full record

ArticlePharmacognosy magazine2017

Arshi Naqvi, Richa Malasoni, Swati Gupta, Akansha Srivastava, Rishi R Pandey, Anil Kumar Dwivedi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacognosy magazine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Arshi NaqviDepartment of Chemistry, Faculty of Science, Taibah University, Al-Madina Al-Munawwara, Kingdom of Saudi Arabia.
Richa MalasoniDivision of Pharmaceutics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Swati GuptaDivision of Pharmaceutics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Akansha SrivastavaDivision of Pharmaceutics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Rishi R PandeyDivision of Pharmaceutics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Anil Kumar DwivediDivision of Pharmaceutics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTurmeric (

objectiveIn this study, we attempted to synthesize a novel chemically modified bioactive fraction from HM (NCCL) along with isolation and characterization of a novel marker compound (I). MATERIALS AND

methodsNCCL was prepared from HM. The chemical structure of the marker compound isolated from NCCL was determined from 1D/2D nuclear magnetic resonance, mass spectroscopy, and Fourier transform infrared. The compound so isolated was subjected to

resultsMolecular docking studies revealed that the binding poses of the compound I was energetically favorable. Among NCCL and compound I taken for

conclusionThis is the first study about the synthesis of a chemically modified bioactive fraction which used a standardized extract since the preparation of the HM. It may be concluded that NCCL fraction having residual components induce more cell death than compound I alone. Thus, NCCL may be used as a potent therapeutic drug. SUMMARY: In the present paper, a standardized hexane soluble fraction of

Indexed as

Anti-cancerCurcuma longaisolationmolecular dockingsynthesis

Identifiers

PMID29142426
PMCPMC5669109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.